Home Search
bladder cancer - search results
If you're not happy with the results, please do another search
FOXA1’s Prostate Tumor-Driving Mechanisms Revealed
Researchers have uncovered three ways FOXA1 (Forkhead box A1) gene mutations override normal biology to drive an estimated one-third of prostate cancers. Dubbed FAST,...
BGI Genomics to Commercialize Natera’s Signatera Assay in China
Signatera’s methodology differs from current liquid biopsy tests, which test for a fixed panel of therapeutically relevant genes
Bio-Techne to Acquire Exosome Diagnostics for Up to $575M
The deal will position Bio-Techne as a leader in non-invasive liquid biopsies and diagnostics for CAR-T cancer therapies
Genoptix Terminates Planned $10M Acquisition of Rosetta Genomics
Companies say Genoptix interested in 'alternative options' after fewer Rosetta shareholders approve the deal than needed for completion
DxTerity, City of Hope Collaborate on Test to Predict Efficacy of Radiation Therapy
The work is part of the RADIANT study to validate DxTerity's blood test for identifying patients likely to benefit from radiation treatment.
Biocept to Study CTC Diagnostics Platform for Immunotherapy Targets
Company taps researcher Dr. Shilp Gupta to observe performance of its technology for detecting PD-L1 and AR in bladder and prostate cancer.
MDx Health Buys NovioGendix for Up to $8.8M
MDx Health plans to acquire NovioGendix for up to $8.8 million, the companies said today, in a deal that expands the buyer’s uro-oncology offerings...
Rosetta Genomics to Acquire PersonalizeDx
Rosetta Genomics said today it has agreed to acquire CynoGen, which does business as PersonalizeDx, from Prelude, in a purchase that expands the buyer’s...
